Opinion

Video

Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer

Author(s):

Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH explains that treatment decisions for metastatic breast cancer are based on the current biopsy showing receptor status, but prior biopsies over the full course of disease are considered as well, particularly for HER2 targeted therapies which may work even if HER2 low expression occurred years earlier.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Photo of Hideko Warner
Picture of LaShae D. Rolle
Photo of Jake Messier
Related Content
Bonnie Annis is a breast cancer survivor, diagnosed in 2014 with stage 2b invasive ductal carcinoma with metastasis to the lymph nodes. Catch up on all of Bonnie's blogs here!
August 16th 2025

Breast Cancer Continues to Teach Me to Appreciate Life

Bonnie Annis
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
August 16th 2025

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
Real-world data show the benefit of Enhertu and Trodelvy across HR+, HER2-null, and HER– disease: © stock.adobe.com.
August 16th 2025

Real-World Data on Treatment Outcomes in HER2-Negative Breast Cancer

Spencer Feldman
Cancer Horizons podcast logo
August 16th 2025

Conference Highlights from SABCS

Alex Biese Brielle Benyon
Patti McGee is an author, a massage therapist and breast cancer survivor of 20 years. Catch up on all of Patti's blogs here!
August 16th 2025

How Community Support Networks Shaped My Journey Through Cancer Care

Patti McGee
Certain gut bacteria were linked to higher risk of heart damage in older patients with breast cancer: © stock.adobe.com.
August 16th 2025

Gut Bacteria May Help Predict Heart Risks in Breast Cancer Treatment

Spencer Feldman